LI-RADS Version 2018 Treatment Response Algorithm: Diagnostic Performance after Transarterial Radioembolization for Hepatocellular Carcinoma by 김경민 et al.
1279Copyright © 2021 The Korean Society of Radiology
INTRODUCTION
The Liver Imaging Reporting and Data System (LI-RADS) 
treatment response algorithm (TRA) standardized image 
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Objective: To assess the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 
treatment response algorithm (TRA) for the evaluation of hepatocellular carcinoma (HCC) treated with transarterial 
radioembolization.
Materials and Methods: This retrospective study included patients who underwent transarterial radioembolization for HCC 
followed by hepatic surgery between January 2011 and December 2019. The resected lesions were determined to have either 
complete (100%) or incomplete (< 100%) necrosis based on histopathology. Three radiologists independently reviewed the 
CT or MR images of pre- and post-treatment lesions and assigned categories based on the LI-RADS version 2018 and the TRA, 
respectively. Diagnostic performances of LI-RADS treatment response (LR-TR) viable and nonviable categories were assessed 
for each reader, using histopathology from hepatic surgeries as a reference standard. Inter-reader agreements were evaluated 
using Fleiss κ.
Results: A total of 27 patients (mean age ± standard deviation, 55.9 ± 9.1 years; 24 male) with 34 lesions (15 with complete 
necrosis and 19 with incomplete necrosis on histopathology) were included. To predict complete necrosis, the LR-TR 
nonviable category had a sensitivity of 73.3–80.0% and a specificity of 78.9–89.5%. For predicting incomplete necrosis, the 
LR-TR viable category had a sensitivity of 73.7–79.0% and a specificity of 93.3–100%. Five (14.7%) of 34 treated lesions 
were categorized as LR-TR equivocal by consensus, with two of the five lesions demonstrating incomplete necrosis. Inter-
reader agreement for the LR-TR category was 0.81 (95% confidence interval: 0.66–0.96).
Conclusion: The LI-RADS version 2018 TRA can be used to predict the histopathologic viability of HCCs treated with 
transarterial radioembolization.
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acquisition, interpretation, reporting, and data collection in 
high-risk patients for hepatocellular carcinoma (HCC) who 
have undergone locoregional therapy (LRT) [1]. Suitable 
for routine clinical practice, it is designed as a simple and 
practical system for evaluating the treatment response of 
individual lesions [1]. In the LI-RADS TRA, post-treatment 
imaging features on contrast-enhanced CT or MRI are 
used to categorize treated lesions based on their LI-RADS 
treatment response (LR-TR), as either LR-TR nonviable 
(probably or definitely not viable), LR-TR equivocal 
(equivocally viable), or LR-TR viable (probably or definitely 
viable) [1]. A precise system for analyzing post-treatment 
imaging is crucial for clinical decision-making, as it aids in 
determining the presence or absence of viable tumors in 
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Transarterial radioembolization (TARE) is an increasingly 
utilized LRT for patients with HCC [3]. TARE, also called 
selective internal radiation therapy, is a transcatheter 
intra-arterial therapy using radioactive substances such 
as microspheres containing yttrium-90 (90Y), iodine-131, 
or similar agents [4,5]. The therapeutic action of TARE is 
predominately radiation-based, whereas its embolic effect is 
less prominent in minimizing alterations in hepatic arterial 
flow compared to other transcatheter therapies [6]. TARE 
is an emerging treatment option in patients who are not 
immediately eligible for surgery because of a large hepatic 
tumor extent or an insufficient residual liver volume [7]. 
TARE has shown promising local tumor control [8-11] and 
can be used on its own to achieve a complete cure or as a 
bridging or downstaging strategy in patients undergoing 
liver transplantation (LT) [3].
Several studies have evaluated the performance of LI-
RADS TRA for the assessment of HCCs treated with various 
types of LRTs, including radiofrequency ablation, microwave 
ablation, transcatheter bland arterial embolization, and 
chemoembolization with or without drug-eluting beads [12-
16]. However, to the best of our knowledge, the diagnostic 
performance of LI-RADS TRA for the evaluation of HCCs 
treated with radiation-based LRTs such as TARE has not yet 
been reported. Therefore, the purpose of our study was to 
assess the diagnostic performance of LI-RADS version 2018 
TRA for the evaluation of HCCs treated with TARE. 
MATERIALS AND METHODS
This retrospective study was approved by the Institutional 
Review Board of Severance Hospital, and the requirement 
to obtain informed consent was waived (IRB No. 4-2020-
0279). The study protocol conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki.
Patients
From a search of our institution’s databases, we identified 
53 patients who first underwent TARE and then subsequent 
hepatic surgery (resection or LT) between January 2011 
and December 2019. The inclusion criteria were as follows: 
1) age 18 years or older; 2) patients at high risk for HCC 
with liver cirrhosis or chronic hepatitis B viral infection; 
and 3) patients who underwent multiphase CT or MRI 
before and after TARE. The exclusion criteria were as 
follows: 1) patients who underwent combined treatment 
with other LRTs or systemic treatment (n = 11); 2) no 
preoperative multiphase CT or MRI examination performed 
within 1 month before surgery (n = 9); and 3) patients 
who were diagnosed with cholangiocarcinoma, combined 
hepatocellular-cholangiocarcinoma, or metastasis on 
histopathology after surgery (n = 3) (Fig. 1).
Lesion Registry and Data Collection
A board-certified abdominal radiologist (with 10 years’ 
experience) marked individual lesions to be reviewed on 
pre- and post-treatment CT or MR imaging, reported the 
Patients who underwent transarterial radioembolization and
subsequent hepatic surgery between 2011 and 2019 (n = 53)
27 patients with 34 treated lesions
Inclusion criteria
  - Patients (≥ 18 years)
  -  Patients with liver cirrhosis or chronic hepatitis B viral 
infection
  -  Patients who underwent multiphase CT or MRI before  
and after transarterial radioembolization
Exclusion criteria
  -  Patients who underwent combined treatment with other 
locoregional therapies or systemic treatment (n = 11)
  -  No preoperative multiphase CT or MRI within one month 
before surgery (n = 9)
  -  Patients diagnosed with CCA, cHCC-CCA or metastasis 
after surgery (n = 3)
Fig. 1. Flowchart of the study population. CCA = cholangiocarcinoma, cHCC-CCA = combined hepatocellular-cholangiocarcinoma
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lesions based on segmental location, and provided a list for 
review. MR images were preferentially considered for image 
analysis. CT images were used when there were no available 
MR images. Clinical and laboratory data were collected from 
electronic medical records of each patient, including age at 
TARE, sex, etiology of liver disease, serum total bilirubin, 
alpha-fetoprotein, and protein induced by vitamin K 
absence or antagonist-II. 
Histopathological data were extracted from pathologic 
reports. Collected histopathological data included 
segmental tumor location, histopathologic diagnosis, and 
histopathologic tumor necrosis (incomplete [< 100%] 
necrosis vs. complete [100%] necrosis).
CT and MRI Examinations
Multiphase CT was performed using 64- or 128-channel 
multidetector CT scanners (Sensation 64 or SOMATOM 
Definition Flash, Siemens Healthineers; LightSpeed VCT, GE 
Healthcare). The protocol included precontrast, late arterial, 
portal venous, and delayed phases. After the precontrast 
scan, contrast-enhanced CT was performed after intravenous 
administration of 2.0 mL/kg iodinated contrast media for 
a fixed injection duration of 30 seconds, followed by a 20-
mL saline flush. The late arterial phase scan was obtained 
18 seconds after the attenuation value reached 100 
Hounsfield unit at the abdominal aorta, using the bolus-
tracking technique. The portal venous phase images were 
acquired 30 seconds after obtaining the late arterial phase, 
and the delayed phase images were acquired 150 seconds 
after obtaining the portal phase images. The CT acquisition 
parameters are presented in Supplementary Table 1.
MRI was performed using a 3T scanner (Magnetom Trio 
Tim, Siemens Healthineers; Intera Achieva, Ingenia, or 
Ingenia CX, Philips Healthcare). The protocol included 
acquisition of dual-echo spoiled gradient-echo T1-weighted 
in-phase and opposed-phase images, single-shot and multi-
shot turbo spin-echo T2-weighted images, and diffusion-
weighted imaging with single-shot echo-planar images 
at b-values of 0, 50, 400, and 800 s/mm2. Dynamic fat-
suppressed spoiled gradient-echo T1-weighted images 
were obtained before and after administering an 
extracellular contrast agent (ECA) (gadoterate meglumine, 
Dotarem, Guerbet SA) or a hepatobiliary agent (HBA) 
(gadoxetate disodium, Primovist, Bayer Pharma AG). 
Bolus injections of 0.2 mL/kg of gadoterate meglumine at 
a rate of 2.0 mL/s or of 0.1 mL/kg gadoxetate disodium 
at a rate of 1.0 mL/s were performed, followed by a 20-
mL saline flush. The choice of MRI contrast agents was 
made at the discretion of the physicians. Arterial phase 
scanning was initiated using the test-bolus or bolus-
tracking techniques, and the portal venous phase (60 
seconds), 3-minute delayed phase (transitional phase on 
HBA-MRI), and 20-minute hepatobiliary phase images (only 
after HBA administration) were evaluated. Detailed MRI 
parameters are presented in Supplementary Table 2.
TARE with Yttrium-90
All patients underwent pretreatment angiography for 
assessing the suitability of treatment and for determining 
dose calculations. Celiac, common hepatic, and cone-
beam CT arteriography were performed to identify feeding 
arteries supplying the tumor and to determine the target 
artery of radioembolization. Technetium-99m-labeled 
macroaggregated albumin was scanned to quantify the lung 
shunt fraction. TARE was performed with resin microspheres 
(SIR-Spheres, Sirtex Medical) or glass microspheres 
(TheraSphere, Biocompatibles UK Ltd) loaded with 90Y. 
The target-absorbed radiation dose of the normal liver 
and lung was determined to not exceed 70 Gy and 25 Gy, 
respectively. TARE was performed only once in each patient.
Image Analysis
Two board-certified abdominal radiologists (reader 1 and 
reader 2, with nine and five years’ experience, respectively) 
and a radiology resident (reader 3, 2nd-year resident) 
independently reviewed each patient’s pre- and post-
treatment CT or MR imaging and evaluated all lesions using 
the CT/MRI LI-RADS version 2018 for pretreatment images 
and the TRA for post-treatment images. All readers were 
blinded to the patients’ clinical information and radiologic 
and histopathologic reports, but were informed that all 
patients had undergone TARE for HCC. 
On pretreatment images, all readers assessed lesion size 
and major imaging features, including nonrim arterial phase 
hyperenhancement (APHE), non-peripheral washout, and 
enhancing capsule appearance. LI-RADS category M (LR-
M; probably or definitely malignant but not HCC specific) 
criteria including the targetoid mass and tumor in vein 
were also evaluated. A pretreatment LI-RADS category 
was assigned to each lesion based on the CT/MRI LI-RADS 
version 2018 [1]. 
On post-treatment/preoperative images, all readers 
assessed the presence or absence of treatment response 




equivocally viable tumor size. The LI-RADS treatment 
response category was determined based on the following 
treatment response features: 1) LR-TR nonviable (probably 
or definitely not viable): no lesional enhancement or a 
treatment-specific expected enhancement pattern including 
a thin rim of enhancement around the treated tumor, 
geographic zone of perilesional enhancement without 
washout appearance, or non-mass-like foci of perilesional 
enhancement without washout appearance; 2) LR-TR 
equivocally viable: indeterminate enhancement defined as 
an enhancement atypical for treatment-specific expected 
enhancement pattern and not meeting criteria for being 
probably or definitely viable; or 3) LR-TR visible (probably 
or definitely viable): nodular, mass-like, or irregular thick 
tissue (NMLIT) in or along the treated lesion with any of 
the following, APHE, washout appearance, or enhancement 
similar to pretreatment [1]. 
APHE was defined as enhancement unequivocally higher 
attenuation or intensity than the liver in the arterial phase 
[1]. When a lesion showed high attenuation or signal 
intensity on precontrast T1-weighted image, APHE was 
evaluated by subtracting the arterial phase image [1]. 
Washout appearance was determined on portal venous or 
delayed phases on CT or MRI examinations with ECA, but 
only on portal venous phase in MRI examinations with HBA 
[1]. In cases with discrepancies between the three readers, 
consensus was determined by agreement between at least 
two readers.
Statistical Analysis
Descriptive data are presented as numbers and 
percentages. Continuous variables are reported as means 
± standard deviations or medians and interquartile ranges 
(IQR). The sensitivity, specificity, accuracy, positive 
predictive value (PPV), and negative predictive value (NPV) 
of LR-TR categories for predicting histopathologic complete 
or incomplete necrosis were calculated for each reader. 
Inter-reader agreements for pre-and post-treatment imaging 
features and for assigned categories were evaluated using 
the Fleiss κ, with 95% confidence intervals (CIs). The κ 
value was interpreted as slight (0.01–0.20), fair (0.21–
0.40), moderate (0.41–0.60), substantial (0.61–0.80), or 
almost perfect (0.81–1.00) [17]. Statistical analyses were 
performed using SPSS version 26.0 (IBM Corp.) and MedCalc 
version 16.2.1 (MedCalc Software). 
RESULTS
Characteristics of Patients and Lesions
A total of 27 patients (mean age, 55.9 years; 24 men 
and three women) with 34 lesions were included in this 
study. The characteristics of the patients and lesions are 
summarized in Table 1. Hepatitis B viral infection (92.6%, 
25 of 27) was the predominant etiology of liver disease in 
these patients. Twenty-one (77.8%) patients had one lesion, 
and six patients (22.2%) had two or three lesions. Twenty 
patients (74.1%) underwent hepatic resections and seven 
(25.9%) underwent LT. The median interval between TARE 
and hepatic surgery was 240 days (IQR, 160–486 days).
The pretreatment imaging examinations included two 
Table 1. Characteristics of Patients and Lesions prior to 
Transarterial Radioembolization
Characteristics Value
Patients n = 27
Age at time of TARE, year* 55.9 ± 9.1
Sex, male:female 24:3
Etiology of liver disease
Hepatitis B 25 (92.6)
Alcohol 2 (7.4)
Total bilirubin level, mg/dL† 0.6 (0.4–0.9)
AFP, ng/mL† 14.0 (3.6–32.7)
PIVKA-II, mAU/mL† 2663 (180–7752)
Operation type
Resection 20 (74.1) 
Transplantation 7 (25.9)
Lesions n = 34





Pretreatment lesion characteristics by consensus
Size, mm* 70.1 ± 30.4
Nonrim APHE 32 (94.1)
Nonperipheral washout appearance 29 (85.3)
Enhancing capsule appearance 22 (64.7)
Targetoid mass 2 (5.9)
TIV 3 (8.8)
Unless otherwise indicated, data are numbers of patients and 
lesions, with percentages in parentheses. *Data are mean ± 
standard deviation, †Data are median with interquartile range 
in parentheses. AFP = alpha-fetoprotein, APHE = arterial phase 
hyperenhancement, LI-RADS = Liver Imaging Reporting and Data 
System, LR = Liver Imaging Reporting and Data System, TIV = 
tumor in vein
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CT examinations, four MRI examinations with ECA, and 21 
MRI examinations with HBA. The pretreatment LI-RADS 
categories for the 34 lesions were determined by consensus 
to be as follows: the majority of lesions (26 of 34, 76.5%) 
were classified as LR-5, three lesions (8.8%) as LR-4, two 
lesions (5.9%) as LR-M, and three lesions (8.8%) as LR-TIV. 
The mean size of pretreatment lesions was 70.1 mm (range, 
10–123 mm). 
Post-Treatment Imaging and Histopathologic Tumor 
Necrosis
The post-treatment imaging examinations included 10 CT 
examinations, one MRI examination with ECA, and 16 MRI 
examinations with HBA. The post-treatment LR-TR categories 
for lesion characteristics by consensus are summarized 
in Table 2. In this study, 44.1% (15 of 34) of treated 
lesions were categorized as LR-TR nonviable by consensus, 
with 12 of the 15 demonstrating complete necrosis on 
histopathology. There were 14.7% (5 of 34) of treated 
lesions categorized as LR-TR equivocal by consensus, with 
two of the five lesions demonstrating incomplete necrosis 
on histopathology. Finally, 41.2% (14 of 34) of treated 
lesions were categorized as LR-TR viable by consensus, with 
all these lesions confirmed to have incomplete necrosis on 
histopathology. All 14 lesions categorized as LR-TR viable 
showed NMLIT with APHE. NMLIT with washout appearance 
and NMLIT with enhancement similar to pretreatment were 
detected in 57.1% (8/14) and 57.1% (8/14) of treated 
lesions, respectively.
Diagnostic Performances of LR-TR Categories
The diagnostic performances of LR-TR categories 
for predicting complete and incomplete necrosis on 
histopathology are presented in Table 3 and Supplementary 
Table 3. For predicting complete necrosis on histopathology, 
the LR-TR nonviable category had a sensitivity ranging 
from 73.3% to 80.0% (12 of 15, 11 of 15, and 11 of 15 for 
readers 1, 2, and 3, respectively) and a specificity ranging 
from 78.9% to 89.5% (15 of 19, 17 of 19, and 16 of 19 
for readers 1, 2, and 3, respectively), with a PPV ranging 
from 75.0% to 84.6% (12 of 16, 11 of 13, and 11 of 14 
for readers 1, 2, and 3, respectively) and an NPV ranging 
from 80.0% to 83.3% (15 of 18, 17 of 21, and 16 of 20 
for readers 1, 2, and 3, respectively) (Fig. 2). To predict 
incomplete necrosis, the LR-TR viable category had a 
sensitivity ranging from 73.7% to 79.0% (14 of 19, 15 of 
19, and 14 of 19 for readers 1, 2, and 3, respectively) and 
a specificity ranging from 93.3% to 100% (15 of 15, 14 of 
15, and 14 of 15 for readers 1, 2, and 3, respectively), with 
a PPV ranging from 93.3% to 100% (14 of 14, 15 of 16, and 
14 of 15 for readers 1, 2, and 3, respectively) and an NPV 
ranging from 73.7% to 77.8% (15 of 20, 14 of 18, and 14 
of 19 for readers 1, 2, and 3, respectively) (Fig. 3).









Complete (100%) necrosis 80.0 (12/15) 60.0 (3/5) 0
Incomplete (< 100%) necrosis 20.0 (3/15) 40.0 (2/5) 100 (14/14)
Post-treatment imaging characteristics
Treatment response features
No lesional enhancement 13.3 (2/15) 0 0
Treatment-specific expected enhancement pattern 86.7 (13/15) 0 0
NMLIT with APHE 0 0 100 (14/14)
NMLIT with washout appearance 0 0 57.1 (8/14)
NMLIT with enhancement similar to pretreatment 0 0 57.1 (8/14)
Indeterminate enhancement* 0  100 (5/5) 0
Size
Whole lesion longest measurement, mm† 37.0 ± 20.0 55.6 ± 15.3 59.1 ± 24.3
Viable or equivocally viable tumor size, mm† 0 ± 0 8.2 ± 1.7 37.9 ± 22.3
Unless otherwise specified, data are percentages and data in parentheses are raw data. *Indeterminate enhancement defined as an 
enhancement atypical for treatment-specific expected enhancement pattern and not meeting criteria being for probably or definitely 
viable, †Data are mean ± standard deviation. APHE = arterial phase hyperenhancement, LR-TR = Liver Imaging Reporting and Data System 





Inter-reader agreement for pre- and post-treatment 
imaging features are summarized in Supplementary Table 4. 
Inter-reader agreement for post-treatment LR-TR category 
was almost perfect (κ = 0.81; 95% CI: 0.66, 0.96). For 
post-treatment imaging features, NMLIT with APHE showed 
the highest agreement (κ = 0.92; 95% CI: 0.73. 1.12), 
followed by NMLIT with enhancement similar to pretreatment 
(κ = 0.75; 95% CI: 0.55, 0.94). Readers were in the lowest 
agreement regarding no lesional enhancement (κ = 0.22; 
95% CI: 0.03, 0.41). 
DISCUSSION
In this study of patients with HCC treated with TARE, the 
LI-RADS version 2018 TRA performed well for predicting 
histopathologic complete necrosis (LR-TR nonviable 
category: sensitivity = 73.3–80.0%; specificity = 78.9–
89.5%) and incomplete necrosis (LR-TR viable category: 
sensitivity = 73.7–79.0%; specificity = 93.3–100%). Five 
(14.7%) of 34 treated lesions were assigned a LR-TR 
equivocal category by consensus, and two of these lesions 
showed incomplete necrosis on histopathology.
Previous studies have assessed the performance of the 
LR-TR nonviable category for other types of LRTs. In a 
study of bland arterial embolization, Shropshire et al. 
[12] showed that less than half of the lesions (38–46%) 
classified as LR-TR nonviable had complete histopathologic 
tumor necrosis. Seo et al. [14] reported that approximately 
two-thirds of LR-TR nonviable lesions (60–64%) were 
confirmed to have complete necrosis after transcatheter 
chemoembolization or radiofrequency ablation. In our 
study, 80.0% (12 of 15) of TARE-treated lesions categorized 
as LR-TR nonviable by consensus were completely necrotic 
on histopathology, which is a higher percentage than 
previously reported in studies investigating other types 
of LRTs [13,14]. This difference may be related to the 
characteristics of the individual treatment modality. In 
addition, the NPV of the LR-TR nonviable category for 
prediction of complete tumor necrosis ranged from 80.0% 
to 83.3%. This high NPV suggests that it may be prudent 
to consider continued imaging surveillance without 
additional treatments in patients with this treatment 
response category after TARE [2].
The LR-TR viable category has also been evaluated in 
previous studies of LRTs. While we found that the LR-TR 
viable category had a sensitivity of 73.7% to 79.0% for 
predicting incomplete tumor necrosis after TARE, previously 
reported studies utilizing conventional chemoembolization 
and post-treatment CT imaging evaluations showed 
lower sensitivities for this category [14,16]. It has been 
suggested that beam-hardening artifacts of lipiodolized 
nodules after conventional chemoembolization may 
obscure precise evaluation of APHE on CT imaging and may 
underestimate residual viable tumors [18]. Our study also 
demonstrated that the LR-TR viable category had a high 
specificity of 93.3% to 100%. This finding is comparable 
to the specificity values reported in previous studies 
Table 3. Diagnostic Performances for Predicting Histopathologic Incomplete Tumor Necrosis in the LR-TR Viable Category and 
Complete Necrosis in the LR-TR Nonviable Category
Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%)




































































Data in parenthesis are the raw data, and data in brackets are the 95% confidence interval. LR-TR = Liver Imaging Reporting and Data 
System treatment response, NPV = negative predictive value, PPV = positive predictive value
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evaluating LI-RADS TRA in patients with HCC and comparing 
tumor viability to histopathology [13-15]. The LI-RADS 
TRA may achieve this high specificity by preventing false-
positive diagnoses based on treatment-specific changes 
[16]. In clinical practice, the high specificity of this 
algorithm for identifying viable tumors in treated lesions is 
crucial for avoiding unnecessary additional treatments. 
Among the characteristic imaging findings for the LR-
Fig. 2. Axial gadoxetate disodium–enhanced magnetic resonance images of a 53-year-old male with chronic hepatitis B and 
hepatocellular carcinoma. 
A. Pretreatment arterial phase T1-weighted 3D gradient-echo image. B. Pretreatment portal venous phase T1-weighted 3D gradient-echo image. 
C. Post-treatment arterial phase T1-weighted 3D gradient-echo image. D. Post-treatment portal venous phase T1-weighted 3D gradient-echo 
image. A, B. Pretreatment (A) arterial and (B) portal venous phase T1-weighted 3D gradient-echo images show a 57-mm lesion with arterial 
phase hyperenhancement, non-peripheral washout, and enhancing capsule appearance (arrows), categorized as LR-5 by the LI-RADS version 
2018. C, D. Post-treatment (C) arterial and (D) portal venous phase T1-weighted 3D gradient-echo images, obtained 186 days after transarterial 
radioembolization, show a decrease in the size of the treated lesion to 23 mm, with no residual enhancement except a thin enhancing rim, 
without any lesion-associated washout (arrows). This lesion is categorized as LI-RADS treatment response nonviable by the LI-RADS version 2018 
treatment response algorithm and was confirmed to have complete necrosis on histopathology after hepatic resection. LI-RADS = Liver Imaging 








TR viable category, our study found that NMLIT with APHE 
was the most frequently observed feature in patients 
with HCC treated with TARE, a finding that is consistent 
with a previous study evaluating imaging findings after 
locoablative therapy [13]. Although the LI-RADS TRA 
assesses tumor viability using several imaging features, 
Fig. 3. Axial gadoxetate disodium–enhanced magnetic resonance images of a 48-year-old male with chronic hepatitis B and 
hepatocellular carcinoma. 
A. Pretreatment arterial phase T1-weighted 3D gradient-echo image. B. Pretreatment portal venous phase T1-weighted 3D gradient-echo image. C. 
Post-treatment arterial phase T1-weighted 3D gradient-echo image. D. Post-treatment portal venous phase T1-weighted 3D gradient-echo image. 
A, B. Pretreatment (A) arterial and (B) portal venous phase T1-weighted 3D gradient-echo images show a 99-mm lesion with APHE and non-
peripheral washout appearance, categorized as LR-5 by LI-RADS version 2018. C, D. Post-treatment (C) arterial and (D) portal venous phase T1-
weighted 3D gradient-echo images, obtained 378 days after transarterial radioembolization, show a decrease in the size of the treated lesion to 51 
mm, with a 22-mm nodular, mass-like, or irregular thick tissue in the treated lesion demonstrating APHE and a washout appearance (arrows). This 
lesion is categorized as LI-RADS treatment response viable by the LI-RADS version 2018 treatment response algorithm and was confirmed to have 
incomplete necrosis on histopathology after hepatic resection. APHE = arterial phase hyperenhancement, LI-RADS = Liver Imaging Reporting and 
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including NMLIT with APHE, washout appearance, and 
enhancement similar to pretreatment, NMLIT with APHE 
appears to be predominantly used for identifying incomplete 
tumor necrosis, with other imaging features providing 
complementary information.
The LR-TR equivocal category reflects uncertainty in 
assessing tumor viability on post-treatment imaging, 
with lesions showing enhancement that is atypical for 
treatment-specific expected enhancement patterns and 
does not meet the criteria for being probably or definitely 
viable. Our study demonstrated that 40% (two of five) of 
LR-TR equivocal lesions were identified to have incomplete 
necrosis after TARE, and 60% (three of five) were confirmed 
to have complete necrosis on histopathology. After TARE, 
patchy arterial enhancement can be seen in treated tumors 
due to post-treatment inflammatory changes [19]. Evolving 
parenchymal abnormalities surrounding the treated tumors 
may also confound the apparent attenuation/signal and 
enhancement characteristics of lesions [20]. These post-
TARE changes may cause lesions to be classified as LR-TR 
equivocal, though they do not have residual viable tumor 
identified on histopathology.
This study had several limitations. The retrospective, 
single-center design introduced an unavoidable selection 
bias. In addition, the number of patients and lesions 
included in this study was relatively small. In addition, 
our study was restricted to patients with HCC who were 
treated with TARE and who underwent subsequent hepatic 
surgery; accordingly, histopathologic necrosis could be 
used as a reference standard. Our exclusive focus on this 
patient population can be considered a strength of this 
study, as it provided potentially valuable information 
about the performance of the LI-RADS TRA for this specific 
type of LRT, which has not previously been evaluated. 
Alternatively, it could be considered a weakness, as we 
did not evaluate the performance of the LI-RADS TRA 
for other types of LRTs, including locoablative therapies, 
other transcatheter therapies, and external beam radiation 
therapy. Another limitation of our study was the use of 
heterogeneous imaging modalities (i.e., CT, MRI with ECA, 
and MRI with HBA) used for image analysis. It is already 
known that background liver affects the detection of LI-
RADS imaging features in CT rather than in MRI [21]. In 
addition, subtraction AP imaging of MRI with HBA improves 
diagnostic performance of HCC in the LR-5 category [22], 
whereas subtraction AP imaging is not available on CT. 
Thus, the heterogeneous imaging modality itself provides 
heterogeneous diagnostic performance. Furthermore, we 
were not able to explore differences in the performance 
of the LI-RADS TRA based on imaging modality (i.e., CT 
vs. MRI) due to insufficient numbers. Further prospective 
studies conducted at multiple centers with larger numbers 
of patients and lesions are needed to determine and 
compare the performance of LI-RADS TRA for different types 
of LRTs and imaging modalities. Lastly, the heterogeneous 
readers’ experience of image interpretation in our study was 
another limitation.
In conclusion, our study demonstrates that the LI-RADS 
version 2018 TRA shows good performance for HCCs treated 
with TARE when lesions are assessed as LR-TR viable or 
nonviable. The LI-RADS version 2018 TRA can be used to 
predict the histopathologic viability of HCCs treated with 
TARE. Further prospective studies with a large multicenter 
multi-reader setting are required to validate the performance 
of the LI-RADS version 2018 TRA in patients with HCC treated 
with TARE and other LRTs. A comparative study between 
imaging modalities and techniques will also be valuable.
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